\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\AtBeginDocument{\let\citet\cite\let\citep\cite}
\usepackage[numbers,sort&compress,numbers,sort&compress]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{https://ijrps.com}{\color{blue}\underline{\smash{https://ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Feature enabled:
%citation-style: unsrt
%citation-type: numbered
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[flushleft]{threeparttablex}

\usepackage{float}

\begin{document}


\def\RunningAuthor{Sudesh N Gaidhani et al.}
\firstPage{403}
\articleType{Original Article}
\receivedDate{20 Sep 2022}
\acceptedDate{29 Oct 2022}
\revisedDate{27 Oct 2022}
\journalVolume{2022, 13}
\journalIssue{4}
\journalDoi{ijrps.v13i4.3835}
\copyrightYear{2022}
\issuelogo{2a083ea5-3f5f-4c89-b3ee-a9be358d63fa-unew-logo}
\issuelogoex{png}
\def\authorCount{5}
\def\affCount{3}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{\textbf{High Fat Diet and Low Dose Streptozotocin Induced Diabetic Dyslipidaemia and Hepatic Damage in Rats}}
\author{Sudesh~N.~Gaidhani\textsuperscript{*}\textsuperscript{1},  
            Viswanth~Reddy~S.\textsuperscript{1},  
            Srikanth~Ala\textsuperscript{1},  
            Sudhakar~D.\textsuperscript{2}, 
            Sanjaya~Kumar~Y.~R.\textsuperscript{3}~\\[5pt]{\textsuperscript{1}Department of Pharmacology, National Ayurveda Research Institute Panchakarma, Cheruthuruthy, Thrissur-679 531, Kerala, India}~\\{\textsuperscript{2}Department of Pharmacology, Central Council for Research in Ayurvedic Sciences, New Delhi, India}~\\{\textsuperscript{3}National Ayurveda Research Institute for Panchakarma, Cheruthuruthy, Thrissur-679531, Kerala, India}}

\begin{abstract}
The objective of the present study was to validate a rat model of diabetic dyslipidaemia along with hepatic damage by High fat diet and low dose streptozotocin combination that resembles the natural history of metabolic syndrome in humans. Male and Female \textit{Sprague Dawley} rats were divided into 2 groups. One group of rats fed with high fat diet and other group was fed with normal pellet diet for a period of 2 weeks followed by streptozotocin administration on 15\ensuremath{^{th}} day. Body weight of the animals was measured on day 0, 14 and 21, also post 1 week of the streptozotocin administration the blood glucose, serum lipid, liver, kidney markers and insulin levels were measured. The high fat diet fed animals had exhibited a significant increase in body weight post two weeks of HFD feeding, but the body weight was reduced post 1 week of streptozotocin intervention due to metabolic disruption caused by STZ. The HFD group animals exhibited significant increase in blood glucose, serum total cholesterol, triglycerides, LDL, VLDL. Similarly, a significant decrease in HDL and serum insulin levels were observed as compared to the NPD fed animals. Further the HFD group animals had shown significant elevation of the liver function enzymes such as ALT and ALP levels as compared to the NPD fed animals. The present study confirms the experimental induction of diabetic dyslipidaemia along with hepatic damage which serves as an ideal model for metabolic syndrome along with hepatic cirrhosis which would useful for evaluating the therapeutic agents against type 2 diabetes, hyperlipidaemia and hepatic cirrhosis. 
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}HFD,\newline STZ,\newline NPD,\newline Metabolic syndrome,\newline Diabetic Dyslipidaemia,\newline Insulin,\newline Hepatic Cirrhosis
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Sudesh~N.~Gaidhani~\\ Phone:\ -~\\  Email:\ sudeshgaidhani@gmail.com
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{https://ijrps.com}{https://ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
Diabetes is a chronic progressive disorder which impairs the metabolism of blood glucose. The most common type of diabetes is of Type-2. Type 2 diabetes has strong links with obesity as per the report given by the national institution of diabetes and digestive and kidney diseases. The important risk factors of diabetes are family history, sedentary lifestyle, overweight, high cholesterol and blood pressure \unskip~\cite{1590750:26459096}.\textbf{\space }

Obesity is related with decreased physical inactivity which increases the risk of diabetes. Studies have reported that increased intake high rich calorie food may be predisposed to diabetes mellitus. Reduced intake of calories decreases the risk of diabetes and improves the tissue sensitivity of insulin. Regular physical activity lowers the blood sugar levels in obese patients by increasing the uptake of glucose by body cells \unskip~\cite{1590750:26459095}.\textbf{\space }

The prevalence of diabetes in India has significantly increased in recent years and as per the report of ICMR, it is prevalent in 13\% of urban and rural population. Balanced diet and lifestyle changes are essential in the management and most of the people require pharmacological intervention to manage blood sugar levels and its complications \unskip~\cite{1590750:26459093}.

Hence it is necessary to explore wide variety of options for the effective management of diabetes mellitus. The preclinical screening models of type 2 diabetes should reflect the human type 2 diabetes such as insulin resistance/lower insulin secretion instead of total beta cell damage as observed in type 1 diabetes mellitus. Although Non-Obese Type 2 diabetes models such as Goto{\textendash}Kakizaki (GK) rats and hIAPP mice are employed in diabetes research, they are limited in usage due to their inability to mimic the human pathological scenario. Administration of streptozotocin alone results in pancreatic \ensuremath{\beta }-cell destruction that may lead to type-1 DM and also High Fat Diet feeding alone showed increased pancreatic \ensuremath{\beta }-cell mass, enhanced insulin secretion, and exocytosis \unskip~\cite{1590750:26459094}.\textbf{\space }This can be overcome by administration of low-dose streptozotocin (35mg/kg) after priming the pancreatic beta cells with significant duration of high-fat diet administration cannot produce extensive destruction of beta cell, rather produces mild to moderate hypoinsulinaemia and hyperglycaemia. This stands as an explanatory mechanism behind successful induction of type 2 diabetes with high fat diet {\textendash} low dose streptozotocin model. 

In the current study, the high-fat diet and low dose of streptozotocin was selected as a model for induction of type-2 diabetes mellitus in \textit{Sprague Dawley} rats and also to evaluate the impact of this model on status of lipid and liver markers which resembles the diabetic dyslipidaemia along with hepatic damage.
    
\section{Materials and Methods}
\textbf{Animals}

The study was performed in male and female \textit{Sparge Dawley} rats. Animals were procured from the small animal veterinary breeding station, Mannuthy, Thrissur, Kerala. The study was conducted as per the recommendations of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines for Laboratory Animal Facility after approval of Institutional Animal Ethics Committee (IAEC/NARIP/2018-19/02), NARIP, Cheruthuruthy.

\textbf{Feed and High-Fat Diet}

High-fat diet was procured from National Institute of Nutrition, Hyderabad. The composition of high fat diet includes the 58\% Fat, 25\% Protein and 17\% Carbohydrates \unskip~\cite{1590750:26459101}.

One kg of High Fat Diet comprises of following ingredients


  
  \begin{enumerate}
  \item \relax Powdered NPD:365 g 
  \item \relax Lard: 310 g
  \item \relax Casein: 250 g
  \item \relax Cholesterol: 10 g 
  \item \relax Vitamin and Mineral mix: 60 g
  \item \relax D-L-Methionine: 03 g
  \item \relax Yeast Powder: 01 g 
  \item \relax Sodium Chloride: 01 g
  \end{enumerate}
  Streptozotocin: Streptozotocin was procured from Sigma Aldrich (CAS no. 18883-66-4).

\textbf{Environment, Housing Acclimatization}

One animal was housed in a cage which was designed for Rat. Each cage was identified with cage card, which displayed with study number, cage number, sex, duration of study and animal identification number. Animals were free access to food and water ad. libitum. Animals were acclimatized for 1 week before initiating the study.

\textbf{Methodology\textit{}}

The study was conducted as per the procedure described by Sreenivasan et. Al. The male and female SD rats were randomized based on body weight. The study design was mentioned in the Table~\ref{tw-bd84ba1c7829}. One group of male and female rats serves as high fat diet control which were maintained on high fat diet for a period of 2 weeks. On day 15\ensuremath{^{th}}, low dose of streptozotocin (35 mg/kg) was injected intraperitoneally to these animals. Similarly, another groups male and female rats were maintained with normal pellet diet for 2 weeks and without streptozotocin intervention on day 15. 

The body of the animals of the current study was measured prior to start of the study (day 0), two weeks after feeding of HFD/NPD (14\ensuremath{^{th}} day) and also post one week of streptozotocin administration. The blood glucose and other biochemical parameters were measured after two weeks of HFD feeding and post 1 week of streptozotocin administration \unskip~\cite{1590750:26459101}.


\begin{table*}[!htbp]
\caption{\boldmath {Study Design} }
\label{tw-bd84ba1c7829}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.16069999999999997\linewidth-2\tabcolsep}p{\dimexpr.2481000000000001\linewidth-2\tabcolsep}p{\dimexpr.30589999999999993\linewidth-2\tabcolsep}p{\dimexpr.2853\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Group  & \cAlignHack No of animals  & \cAlignHack Feed for 2 weeks  & \cAlignHack STZ intervention \\
\tblmidrule 
\cAlignHack NPDM  &
  \cAlignHack 03  &
  \cAlignHack Normal pellet diet  &
  \cAlignHack NO \\
\cAlignHack NPDF  &
  \cAlignHack 03  &
  \cAlignHack Normal pellet diet  &
  \cAlignHack NO \\
\cAlignHack HFDM  &
  \cAlignHack 03  &
  \cAlignHack High fat diet  &
  \cAlignHack YES \\
\cAlignHack HFDF  &
  \cAlignHack 03  &
  \cAlignHack High fat diet  &
  \cAlignHack YES \\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{NPDM- Normal pellet diet male, NPDF- Normal pellet diet Female, HFDM- High fat diet male, HFDF- High fat diet Female, STZ- Streptozotocin}
\end{tablenotes}
\end{threeparttable}

\end{table*}
\textbf{Estimation of Insulin}

Serum insulin levels were determined post 1 week of streptozotocin administration using ELISA kit (BT LAB, Ct.No. E0707 Ra) as per the manufacturer instructions.

\textbf{Statistical Analysis}

Results obtained from the present study were expressed as Mean \ensuremath{\pm}SEM. Data was subjected to statistical analysis through one way analysis of variance (ANOVA) with multiple comparisons using Sidak's test by using Graph pad prism software. p{\textless}0.05 was considered as statistically significant.
    
\section{Results}
\textbf{Glucose}

The blood glucose levels of all the groups were checked on day 0 (prior to start of the study) and 21\ensuremath{^{st}} day (post 1 week of streptozotocin administration). No significant difference in blood glucose levels were observed in high fat diet animals as compared to the normal pellet diet animals on day 0. After streptozotocin intervention the high fat diet fed animals has shown significant increase in the blood glucose levels (p{\textless}0.0001) [Table~\ref{tw-a22c450e933e} and Figure~\ref{f-489fa181edc5}].


\begin{table*}[!htbp]
\caption{\boldmath {Blood Glucose Levels (mg/dl)} }
\label{tw-a22c450e933e}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2366\linewidth-2\tabcolsep}p{\dimexpr.4193000000000001\linewidth-2\tabcolsep}p{\dimexpr.3441\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Group  & \cAlignHack Day 0  & \cAlignHack Day 21 \\
\tblmidrule 
\cAlignHack NPDM  &
  \cAlignHack 107\ensuremath{\pm}03  &
  \cAlignHack 109\ensuremath{\pm}13 \\
\cAlignHack NPDF  &
  \cAlignHack 98\ensuremath{\pm}08  &
  \cAlignHack 105\ensuremath{\pm}06 \\
\cAlignHack HFDM  &
  \cAlignHack 86\ensuremath{\pm}03\ensuremath{^{@ns}} &
  \cAlignHack 334\ensuremath{\pm}11\ensuremath{^{@****}}\\
\cAlignHack HFDF  &
  \cAlignHack 105\ensuremath{\pm}02\ensuremath{^{\$ns }} &
  \cAlignHack 381\ensuremath{\pm}10\ensuremath{^{\$****}}\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{NPDM-Normal pellet diet male, NPDF- Normal pellet diet Female, HFDM- High fat diet male, HFDF- High fat diet Female}
    
\item{[Values are expressed as mean \ensuremath{\pm} SEM of 3 rats] \ensuremath{^{****}}p{\textless}0.0001; \ensuremath{^{ns}}-Non significant; Data was subjected to analysis through one-way ANOVA with Sidak's multiple comparison test; The comparison is as follows; @-comparsion of HFDM with NPDM; \$- comparison of HFDF with NPDF}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Serum Cholesterol and Lipid Levels (mg/dl)} }
\label{tw-1c731343b02c}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.0855\linewidth-2\tabcolsep}p{\dimexpr.0945\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.0953\linewidth-2\tabcolsep}p{\dimexpr.0947\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Group & \multicolumn{2}{p{\dimexpr(.1845\linewidth-2\tabcolsep)}}{\cAlignHack Chol (mg/dl)} & \multicolumn{2}{p{\dimexpr(.18\linewidth-2\tabcolsep)}}{\cAlignHack LDL (mg/dl)} & \multicolumn{2}{p{\dimexpr(.18\linewidth-2\tabcolsep)}}{\cAlignHack HDL (mg/dl)} & \multicolumn{2}{p{\dimexpr(.18\linewidth-2\tabcolsep)}}{\cAlignHack VLDL (mg/dl)} & \multicolumn{2}{p{\dimexpr(.19\linewidth-2\tabcolsep)}}{\cAlignHack TRI (mg/dl)}\\
\rowcolor{kwdboxcolor}\cAlignHack  & \cAlignHack Day 0  & \cAlignHack Day 21  & \cAlignHack Day 0  & \cAlignHack Day 21  & \cAlignHack Day 0  & \cAlignHack Day 21  & \cAlignHack Day 0  & \cAlignHack Day 21  & \cAlignHack Day 0  & \cAlignHack Day 21 \\
\tblmidrule 
\cAlignHack NPDM  &
  \cAlignHack 85\ensuremath{\pm}04  &
  \cAlignHack 80\ensuremath{\pm}02  &
  \cAlignHack 22\ensuremath{\pm}01  &
  \cAlignHack 26\ensuremath{\pm}02  &
  \cAlignHack 46\ensuremath{\pm}03  &
  \cAlignHack 49\ensuremath{\pm}01  &
  \cAlignHack 18\ensuremath{\pm}03  &
  \cAlignHack 15\ensuremath{\pm}02  &
  \cAlignHack 88\ensuremath{\pm}15  &
  \cAlignHack 77\ensuremath{\pm}08 \\
\cAlignHack NPDF  &
  \cAlignHack 96\ensuremath{\pm}02  &
  \cAlignHack 88\ensuremath{\pm}03  &
  \cAlignHack 17\ensuremath{\pm}05  &
  \cAlignHack 11\ensuremath{\pm}04  &
  \cAlignHack 64\ensuremath{\pm}01  &
  \cAlignHack 57\ensuremath{\pm}04  &
  \cAlignHack 15\ensuremath{\pm}03  &
  \cAlignHack 20\ensuremath{\pm}03  &
  \cAlignHack 75\ensuremath{\pm}16  &
  \cAlignHack 97\ensuremath{\pm}17 \\
\cAlignHack HFDM  &
  \cAlignHack 81\ensuremath{\pm}03 \ensuremath{^{@ns}} &
  \cAlignHack 209\ensuremath{\pm}44 \ensuremath{^{@*}} &
  \cAlignHack 21\ensuremath{\pm}02 \ensuremath{^{@ns}} &
  \cAlignHack 127\ensuremath{\pm}29 \ensuremath{^{@**}} &
  \cAlignHack 48\ensuremath{\pm}03 \ensuremath{^{@ns}} &
  \cAlignHack 30\ensuremath{\pm}05 \ensuremath{^{@*}} &
  \cAlignHack 12\ensuremath{\pm}02 \ensuremath{^{@ns}} &
  \cAlignHack 46\ensuremath{\pm}06 \ensuremath{^{@*}} &
  \cAlignHack 60\ensuremath{\pm}07 \ensuremath{^{@ns}} &
  \cAlignHack 228\ensuremath{\pm}38 \ensuremath{^{@* }}\\
\cAlignHack HFDF &
  \cAlignHack 80\ensuremath{\pm}10 \ensuremath{^{\$ns}} &
  \cAlignHack 264\ensuremath{\pm}40 \ensuremath{^{\$**}} &
  \cAlignHack 12\ensuremath{\pm}02 \ensuremath{^{\$ns}} &
  \cAlignHack 159\ensuremath{\pm}22 \ensuremath{^{\$***}} &
  \cAlignHack 55\ensuremath{\pm}05 \ensuremath{^{\$ns}} &
  \cAlignHack 31\ensuremath{\pm}04 \ensuremath{^{\$**}} &
  \cAlignHack 12\ensuremath{\pm}03 \ensuremath{^{\$ns}} &
  \cAlignHack 69\ensuremath{\pm}10 \ensuremath{^{\$**}} &
  \cAlignHack 62\ensuremath{\pm}15 \ensuremath{^{\$ns}} &
  \cAlignHack 344\ensuremath{\pm}48 \ensuremath{^{\$** }}\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{NPDM-Normal pellet diet male, NPDF- Normal pellet diet Female, HFDM- High fat diet male, HFDF- High fat diet Female}
    
\item{[Values are expressed as mean \ensuremath{\pm} SEM of 3 rats]\ensuremath{^{ *}}p{\textless}0.05, \ensuremath{^{**}}p{\textless}0.01; \ensuremath{^{***}}p{\textless}0.001; \ensuremath{^{****}}p{\textless}0.0001;\ensuremath{^{ ns}}- Non significant; Data was subjected to analysis through one way ANOVA with Sidak's multiple comparison test; @-comparison of HFDM with NPDM, \$- comparison of HFDF with NPDF}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Liver Enzyme Levels} }
\label{tw-bccd7a9602e7}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.1294\linewidth-2\tabcolsep}p{\dimexpr.1506\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.16\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Group & \multicolumn{2}{p{\dimexpr(.29060000000000002\linewidth-2\tabcolsep)}}{\cAlignHack AST (U/L)} & \multicolumn{2}{p{\dimexpr(.28\linewidth-2\tabcolsep)}}{\cAlignHack ALT (U/L)} & \multicolumn{2}{p{\dimexpr(.30\linewidth-2\tabcolsep)}}{\cAlignHack ALP (U/L)}\\
\rowcolor{kwdboxcolor}\cAlignHack  & \cAlignHack Day 0  & \cAlignHack Day 21  & \cAlignHack Day 0  & \cAlignHack Day 21  & \cAlignHack Day 0  & \cAlignHack Day 21 \\
\tblmidrule 
\cAlignHack NPDM  &
  \cAlignHack 103\ensuremath{\pm}03 &
  \cAlignHack 164\ensuremath{\pm}06  &
  \cAlignHack 54\ensuremath{\pm}04  &
  \cAlignHack 56\ensuremath{\pm}04  &
  \cAlignHack 228\ensuremath{\pm}33  &
  \cAlignHack 279\ensuremath{\pm}78 \\
\cAlignHack NPDF  &
  \cAlignHack 88\ensuremath{\pm}06  &
  \cAlignHack 113\ensuremath{\pm}13  &
  \cAlignHack 46\ensuremath{\pm}02  &
  \cAlignHack 55\ensuremath{\pm}07  &
  \cAlignHack 146\ensuremath{\pm}14  &
  \cAlignHack 267\ensuremath{\pm}43 \\
\cAlignHack HFDM  &
  \cAlignHack 147\ensuremath{\pm}39\ensuremath{^{@ns}} &
  \cAlignHack 162\ensuremath{\pm}03\ensuremath{^{@ns}} &
  \cAlignHack 62\ensuremath{\pm}09\ensuremath{^{@ns}} &
  \cAlignHack 103\ensuremath{\pm}06\ensuremath{^{@**}} &
  \cAlignHack 159\ensuremath{\pm}05\ensuremath{^{@ns}} &
  \cAlignHack 726\ensuremath{\pm}53\ensuremath{^{@** }}\\
\cAlignHack HFDF &
  \cAlignHack 89\ensuremath{\pm}03\ensuremath{^{\$ns}} &
  \cAlignHack 132\ensuremath{\pm}07\ensuremath{^{\$ns}} &
  \cAlignHack 44\ensuremath{\pm}04\ensuremath{^{\$ns }} &
  \cAlignHack 101\ensuremath{\pm}07\ensuremath{^{\$**}} &
  \cAlignHack 93\ensuremath{\pm}10\ensuremath{^{\$ns}} &
  \cAlignHack 572\ensuremath{\pm}72\ensuremath{^{\$*}}\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{NPDM-Normal pellet diet male, NPDF- Normal pellet diet Female, HFDM- High fat diet male, HFDF- High fat diet Female}
    
\item{[Values are expressed as mean \ensuremath{\pm} SEM of 3 rats] \ensuremath{^{*}}p{\textless}0.05; \ensuremath{^{**}}p{\textless}0.01; \ensuremath{^{ns}}-Non significant; Data was subjected to analysis through one way ANOVA with Sidak's multiple comparison test; @-comparison of HFDM with NPDM, \$- comparison of HFDF with NPDF}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Creatinine (Kidney Marker) Levels} }
\label{tw-893712612726}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.274\linewidth-2\tabcolsep}p{\dimexpr.386\linewidth-2\tabcolsep}p{\dimexpr.34\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Group & \multicolumn{2}{p{\dimexpr(.726\linewidth-2\tabcolsep)}}{\cAlignHack Creatinine (mg/dL)}\\
\rowcolor{kwdboxcolor}\cAlignHack  & \cAlignHack Day 0  & \cAlignHack Day 21 \\
\tblmidrule 
\cAlignHack NPDM  &
  \cAlignHack 0.44\ensuremath{\pm}0.03  &
  \cAlignHack 0.40\ensuremath{\pm}0.01 \\
\cAlignHack NPDF  &
  \cAlignHack 0.56\ensuremath{\pm}0.06  &
  \cAlignHack 0.37\ensuremath{\pm}0.01 \\
\cAlignHack HFDM  &
  \cAlignHack 0.61\ensuremath{\pm}0.13\ensuremath{^{@ns}} &
  \cAlignHack 0.44\ensuremath{\pm}0.03\ensuremath{^{@ns}}\\
\cAlignHack HFDF &
  \cAlignHack 0.53\ensuremath{\pm}0.02\ensuremath{^{\$ns}} &
  \cAlignHack 0.41\ensuremath{\pm}0.03\ensuremath{^{\$ns}}\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{NPDM-Normal pellet diet male, NPDF- Normal pellet diet Female, HFDM- High fat diet male, HFDF- High fat diet Female}
    
\item{[Values are expressed as mean \ensuremath{\pm} SEM of 3 rats];\ensuremath{^{ ns}}-Non significant; Data was subjected to analysis through one way ANOVA with Sidak's multiple comparison test; @-comparison of HFDM with NPDM, \$- comparison of HFDF with NPDF}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Body Weight} }
\label{tw-5c3cff5ab971}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.248\linewidth-2\tabcolsep}p{\dimexpr.2437\linewidth-2\tabcolsep}p{\dimexpr.2583\linewidth-2\tabcolsep}p{\dimexpr.25\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Group & \cAlignHack Day 0  & \cAlignHack Day 14  & \cAlignHack Day 21 \\
\tblmidrule 
\cAlignHack NPDM  &
  \cAlignHack 266\ensuremath{\pm}08  &
  \cAlignHack 281\ensuremath{\pm}08  &
  \cAlignHack 290\ensuremath{\pm}09 \\
\cAlignHack NPDF  &
  \cAlignHack 220\ensuremath{\pm}06  &
  \cAlignHack 235\ensuremath{\pm}06  &
  \cAlignHack 243\ensuremath{\pm}09 \\
\cAlignHack HFDM  &
  \cAlignHack 258\ensuremath{\pm}11\ensuremath{^{@ns}} &
  \cAlignHack 315\ensuremath{\pm}11\ensuremath{^{@*}} &
  \cAlignHack 281\ensuremath{\pm}10\ensuremath{^{@ns}}\\
\cAlignHack HFDF &
  \cAlignHack 231\ensuremath{\pm}02\ensuremath{^{\$ns}} &
  \cAlignHack 271\ensuremath{\pm}08\ensuremath{^{\$* }} &
  \cAlignHack 240\ensuremath{\pm}12\ensuremath{^{\$ns}}\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{NPDM- Normal pellet diet male, NPDF- Normal pellet diet Female, HFDM- High fat diet male, HFDF- High fat diet Female}
    
\item{[Values are expressed as mean \ensuremath{\pm} SEM of 3 rats] \ensuremath{^{*}}p{\textless}0.05; \ensuremath{^{ns}}-Non significant; Data was subjected to analysis through one way ANOVA with Sidak's multiple comparison test; @-comparison of HFDM with NPDM, \$- comparison of HFDF with NPDF}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Insulin (MIU/L) Levels} }
\label{tw-12fe828d5a28}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.4004\linewidth-2\tabcolsep}p{\dimexpr.5996\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\cAlignHack Group & \cAlignHack Day 21\\
\tblmidrule 
\cAlignHack NPDM  &
  \cAlignHack 6.8\ensuremath{\pm}0.2 \\
\cAlignHack NPDF  &
  \cAlignHack 6.0\ensuremath{\pm}0.9 \\
\cAlignHack HFDM  &
  \cAlignHack 2.6\ensuremath{\pm}0.3\ensuremath{^{@***}}\\
\cAlignHack HFDF &
  \cAlignHack 2.4\ensuremath{\pm}0.2\ensuremath{^{\$**}}\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{NPDM- Normal pellet diet male, NPDF- Normal pellet diet Female, HFDM- High fat diet male, HFDF- High fat diet Female}
    
\item{[Values are expressed as mean \ensuremath{\pm} SEM of 3 rats] \ensuremath{^{**}}p{\textless}0.01; \ensuremath{^{***}}p{\textless}0.001;\ensuremath{^{ ns}}-Non significant; Data was subjected to analysis through one way ANOVA with Sidak's multiple comparison test; @-comparison of HFDM with NPDM, \$- comparison of HFDF with NPDF}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\bgroup
\fixFloatSize{images/9483b3ed-9caa-4d96-8393-678cfc88640f-upicture1.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/9483b3ed-9caa-4d96-8393-678cfc88640f-upicture1.png}{\includegraphics{images/9483b3ed-9caa-4d96-8393-678cfc88640f-upicture1.png}}{}
\makeatother 
\caption{\boldmath {Blood Glucose Levels}}
\label{f-489fa181edc5}
\end{figure}
\egroup
\textbf{Cholesterol, LDL, HDL, VLDL and Triglyceride Levels}

The serum Cholesterol, LDL HDL, VLDL \& Triglyceride levels of animals were measured on day 0 (prior to start of the study) and 21\ensuremath{^{st}} day (post 1 week of streptozotocin administration). 

No significant difference in cholesterol and other lipid levels were observed in high fat diet animals as compared to the normal pellet diet animals on day 0 (p{\textgreater}0.05). 

Post streptozotocin administration the high fat diet animals had shown significant (p{\textless}0.05) (p{\textless}0.01) increase in the cholesterol levels, LDL levels  (p{\textless}0.01) (p{\textless}0.001), VLDL(p{\textless}0.05) (p{\textless}0.01) \& Triglyceride (p{\textless}0.05) (p{\textless}0.01) levels. 

Similarly, a significant decrease in HDL levels were observed in streptozotocin treated HFD animals as compared to the NPD animals(p{\textless}0.05) (p{\textless}0.01) [Table~\ref{tw-1c731343b02c}, Figure~\ref{f-5e7c627ac833}, Figure~\ref{f-4d413b4a6d20}, Figure~\ref{f-1b9e117cdba3}, Figure~\ref{f-3bd2e04edd21} and Figure~\ref{f-cd46170d3236}].


\bgroup
\fixFloatSize{images/ddffda48-14c2-443d-9c0d-90fdb07e6dd2-upicture2.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/ddffda48-14c2-443d-9c0d-90fdb07e6dd2-upicture2.png}{\includegraphics{images/ddffda48-14c2-443d-9c0d-90fdb07e6dd2-upicture2.png}}{}
\makeatother 
\caption{\boldmath {Serum Total Cholesterol Levels}}
\label{f-5e7c627ac833}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/49a14e87-eb75-4d4c-95a7-3d20b657809f-upicture3.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/49a14e87-eb75-4d4c-95a7-3d20b657809f-upicture3.png}{\includegraphics{images/49a14e87-eb75-4d4c-95a7-3d20b657809f-upicture3.png}}{}
\makeatother 
\caption{\boldmath {Serum LDL Levels}}
\label{f-4d413b4a6d20}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/aad85d8c-42f0-4ff6-9614-c8035aa6dfb1-upicture4.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/aad85d8c-42f0-4ff6-9614-c8035aa6dfb1-upicture4.png}{\includegraphics{images/aad85d8c-42f0-4ff6-9614-c8035aa6dfb1-upicture4.png}}{}
\makeatother 
\caption{\boldmath {Serum Triglyceride Levels}}
\label{f-1b9e117cdba3}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/ba269a11-9913-4907-a4e9-c39e1489d5da-upicture5.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/ba269a11-9913-4907-a4e9-c39e1489d5da-upicture5.png}{\includegraphics[width=.50\linewidth]{images/ba269a11-9913-4907-a4e9-c39e1489d5da-upicture5.png}}{}
\makeatother 
\caption{\boldmath {Serum VLDL Levels}}
\label{f-3bd2e04edd21}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/e2fb7027-b2a6-4525-af59-117d52f68b8e-upicture6.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/e2fb7027-b2a6-4525-af59-117d52f68b8e-upicture6.png}{\includegraphics[width=.50\linewidth]{images/e2fb7027-b2a6-4525-af59-117d52f68b8e-upicture6.png}}{}
\makeatother 
\caption{\boldmath {Serum HDL Levels}}
\label{f-cd46170d3236}
\end{figure}
\egroup
\textbf{Liver Markers}

The liver enzymes AST, ALT \&ALP levels of animals were measured on day 0 (prior to start of the study) and 21\ensuremath{^{st}} day (post 1 week of streptozotocin administration). 

No significant changes in these enzymes' levels were found in high fat diet animals as compared to the normal pellet diet animals on day 0 (p{\textgreater}0.05).  

Two weeks of high fat diet feeding followed by streptozotocin administration resulted in significant elevation in ALT(p{\textless}0.01) \& ALP(p{\textless}0.05) (p{\textless}0.01) levels, but there are no significant changes in AST levels were seen as compared to the NPD animals (p{\textgreater}0.05) [Table~\ref{tw-bccd7a9602e7}, Figure~\ref{f-93b9e2b5d7e3}, Figure~\ref{f-f58728b10cf4}  and Figure~\ref{f-07ecd967cd2d}].


\bgroup
\fixFloatSize{images/8bc02361-f41d-4405-92eb-23bb42eec324-upicture7.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/8bc02361-f41d-4405-92eb-23bb42eec324-upicture7.png}{\includegraphics{images/8bc02361-f41d-4405-92eb-23bb42eec324-upicture7.png}}{}
\makeatother 
\caption{\boldmath {Serum AST Levels}}
\label{f-93b9e2b5d7e3}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/61b7643c-ddd3-4780-b6ad-9adcdbe07255-upicture8.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/61b7643c-ddd3-4780-b6ad-9adcdbe07255-upicture8.png}{\includegraphics{images/61b7643c-ddd3-4780-b6ad-9adcdbe07255-upicture8.png}}{}
\makeatother 
\caption{\boldmath {Serum ALT Levels}}
\label{f-f58728b10cf4}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/fcb9863e-ba70-49cb-a0f0-5181d9410065-upicture9.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/fcb9863e-ba70-49cb-a0f0-5181d9410065-upicture9.png}{\includegraphics{images/fcb9863e-ba70-49cb-a0f0-5181d9410065-upicture9.png}}{}
\makeatother 
\caption{\boldmath {Serum ALP Levels}}
\label{f-07ecd967cd2d}
\end{figure}
\egroup
\textbf{Kidney Markers}

Creatinine as a kidney marker was measured in the serum. No significant changes creatinine levels were found in high fat diet animals as compared to the normal pellet diet animals on day 0 \& day 21 (p{\textgreater}0.05) [Table~\ref{tw-893712612726}  and Figure~\ref{f-5d6fc50ebd3b}].\textit{\textbf{\space }}


\bgroup
\fixFloatSize{images/e76c3c6e-79ca-48c7-bd77-fc1899c4a8da-upicture10.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/e76c3c6e-79ca-48c7-bd77-fc1899c4a8da-upicture10.png}{\includegraphics{images/e76c3c6e-79ca-48c7-bd77-fc1899c4a8da-upicture10.png}}{}
\makeatother 
\caption{\boldmath {Serum Creatinine Levels}}
\label{f-5d6fc50ebd3b}
\end{figure}
\egroup
\textbf{Body Weight}

Post 2 weeks of high fat diet feeding Significant increase in body weight was observed in HFD group as compared to NPD group animals (p{\textless}0.05). However, streptozotocin administration reduced the body weight hence no significant changes in body weight were observed in HFD animals on 21\ensuremath{^{st}} day as compared to NPD group (p{\textgreater}0.05) [Table~\ref{tw-5c3cff5ab971}  and Figure~\ref{f-5c84b1c50f1c}].


\bgroup
\fixFloatSize{images/9bcbc334-f464-4b3d-ac37-8f905da726af-upicture11.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/9bcbc334-f464-4b3d-ac37-8f905da726af-upicture11.png}{\includegraphics{images/9bcbc334-f464-4b3d-ac37-8f905da726af-upicture11.png}}{}
\makeatother 
\caption{\boldmath {Body Weight}}
\label{f-5c84b1c50f1c}
\end{figure}
\egroup
\textbf{Insulin}

The insulin levels in the serum were measured by using ELISA kit. Streptozotocin intervention in high fat diet fed animals significantly lowered the insulin levels as compared to the NPD fed animals (p{\textless}0.01 \& p{\textless}0.001) [Table~\ref{tw-12fe828d5a28}   and Figure~\ref{f-a82ba626b195}].


\bgroup
\fixFloatSize{images/14bbb382-6360-44bf-9a7c-0a1cb5f02b82-upicture12.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/14bbb382-6360-44bf-9a7c-0a1cb5f02b82-upicture12.png}{\includegraphics{images/14bbb382-6360-44bf-9a7c-0a1cb5f02b82-upicture12.png}}{}
\makeatother 
\caption{\boldmath {Serum Insulin Levels}}
\label{f-a82ba626b195}
\end{figure}
\egroup

    
\section{Discussion }
The study was conducted with the objective of developing diabetic dyslipidaemia along with hepatocellular damage that would reflects natural history and metabolic characteristics of metabolic syndrome along with hepatic cirrhosis which responds to pharmacotherapy.

In this context, the male and female SD rats were fed with HFD and NPD for 2 weeks followed by single i.p injection of streptozotocin to HFD fed animals which produced the frank hyperglycaemia along with hypoinsulinemia similar to reported literature \unskip~\cite{1590750:26459103}.\textbf{\space }

The high fat diet feeding produced the significant increase in bodyweight of HFD group rats as compared with NPD rats. Further the body weight was lowered post STZ treatment due to the catabolic loss induced by low dose STZ. 

The development of rat model of metabolic syndrome along with hepatic damage was performed by feeding of HFD and administering low dose STZ. The high fat diet was procured from NIN, Hyderabad as per the composition described by Sreenivasan et al.\textbf{\space }Streptozotocin induces pancreatic beta cell destruction by redox imbalance and subsequent oxidative stress \unskip~\cite{1590750:26459098}. This combination resulted in hyperglycaemia, hypoinsulinemia, hypercholesterolemia, hypertriglyceridemia and hyperlipidaemia that would closely reflects type-2 diabetes along with dyslipidaemia.

The diabetes also associated with hepato-cirrhosis and hepatocellular carcinoma (HCC) \unskip~\cite{1590750:26459099}. Liver is a key organ of regulation of glucose and lipid metabolism. In type-2 diabetes due to unopposed endogenous glucose production and insulin resistance which leads to hepatic damage caused by hepatic steatosis \unskip~\cite{1590750:26459097}. Hence the liver function tests such as AST, ALT \& ALP are an essential part of clinical evaluation of a diabetic subject \unskip~\cite{1590750:26459100}. Correspondingly, the STZ administered HFD animals showed higher circulating levels of ALT\&ALP which resembles hepatic cirrhosis in type-2 diabetic subjects. 

Kidney also plays an important role in the regulation of blood glucose. The persistent high blood glucose levels result in diabetic nephropathy (DN) which is a progressive decline in renal function, and subsequent end Stage renal failure (ESRF) \unskip~\cite{1590750:26459102}. Creatinine is an important marker evaluating the function of kidney. Higher levels of blood creatine due to under excretion of creatinine has been observed in type 2 diabetes \unskip~\cite{1590750:26459104}.\textbf{\space }

Based on the foregoing observations, the current model can be compared with the literature model by Sreenivasan et al. in the following aspects. Sreenivasan et al. initially developed the rat model of type-2 diabetes with HFD and low dose STZ. Sreenivasan et al. developed the model in male SD rats but the present study was conducted in male and female SD rats to avoid the variation due to sex on model validation. 

Sreenivasan et.al described increase in body weight post STZ treatment in HFD fed animals but the current study establishes consistent decrease in body weight. Further the model was not validated on liver function. In contrary to this, present study the liver enzyme levels AST, ALT and ALP evaluated to establish the hepatic damage caused by STZ and HFD combination. Study also signifies the effect on kidney status by measuring the renal markers such as creatinine levels in serum.
    
\section{Conclusion }
Our study establishes that combination of HFD and single low dose STZ can effectively use a model for diabetic dyslipidaemia along with hepatic damage that reflects the natural history of metabolic syndrome in humans. It is an ideal model for type-2 diabetes along with hyperlipidaemia and hepatic cirrhosis and is useful in evaluating therapeutic compounds for metabolic syndrome.

\textbf{Abbreviations}

AST: Aspartate amino transferase, ALT: Alanine amino transferase, ALP= Alkaline phosphatase, CHO: Cholesterol, CREA: Creatinine, HFD= High fat diet, NPD= Normal pellet diet, HDL: High density lipoprotein, LDL: Low density lipoprotein, NIN: National Institute of Nutrition, OECD= Organization for economic cooperation and development, OGTT: Oral Glucose tolerance test, RH: Relative humidity, TRI: Triglycerides, VLDL: Very Low-density lipoprotein.
    
\section{Acknowledgement}
The authors greatly acknowledge the Director General, Central Council for Research in Ayurvedic Sciences (CCRAS), New Delhi for providing intra mural research (IMR) funding and encouragement.

\textbf{Conflict of Interest}

The authors declare that there is no conflict of interest.
    

\bibliographystyle{unsrt}

\bibliography{\jobname}
\end{document}
